On July 15, HCA Healthcare rose 3.07% in regular trading, trading at $374.82/share, with turnover of $175 million. The rebound follows a sharp selloff of over 8% in the prior session after the company lowered its full-year adjusted diluted EPS guidance.

On the news front, HCA disclosed preliminary Q2 revenue of approximately $20.23 billion, significantly exceeding the FactSet consensus estimate of $19.47 billion. Additionally, the company recognized an extra $400 million in net benefits from a Medicaid supplemental payment plan during the quarter, providing further support for the technical recovery.

The lowered profit outlook had triggered concentrated selling on July 14, compounded by multiple Wall Street banks cutting price targets in recent weeks — with the average analyst target declining from approximately $546 at the start of the year to around $490. However, the strong top-line beat and supplemental payment windfall offered investors a reason to buy the dip.

The broader Health Care Facilities sector rallied in sympathy, with Tenet Healthcare up 4.01%, Acadia Healthcare up 3.69%, Universal Health Services up 2.05%, and Ensign up 1.36%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)